Literature DB >> 23306099

Prostate cancer therapy: going forwards by going backwards.

Christopher Sweeney1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23306099     DOI： 10.1016/S1470-2045(12)70591-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Authors:  Michael T Schweizer; Roman Gulati; Elahe A Mostaghel; Peter S Nelson; R Bruce Montgomery; Evan Y Yu; Heather H Cheng
Journal:  Med Oncol       Date:  2016-06-14       Impact factor: 3.064

2.  Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.

Authors:  Yue Wang; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.